- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06281665
Behandling med aspirin etter svangerskapsforgiftning: TAP-forsøk (TAP)
The objective of this research project is to conduct a single-site pilot trial to assess the feasibility and effect of low-dose aspirin to augment vascular recovery in the immediate postpartum period after preeclampsia through two specific aims: 1) to pilot test the feasibility of conducting a randomized controlled trial of postpartum low dose aspirin vs. placebo, and 2) to assess the effect of postpartum aspirin on endothelial function and blood pressure. Our central hypothesis is that postpartum administration of low-dose aspirin following preeclampsia will be feasible, improve endothelial function, and lower BP at 6 months postpartum. Subjects will undergo 3 study visits involving BP measurements, blood draws, questionnaires, and/or microiontophoresis. Up to 60 adult subjects will be enrolled at Magee-Women's Hospital.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
This is a pilot randomized, single-center, double-blind placebo-control study of low dose aspirin in postpartum individuals with preeclampsia. Individuals will be randomized at the time of delivery 1:1 to 81mg of low-dose aspirin or identical appearing placebo daily for six months postpartum. Treatment and control groups will monitor home blood pressure throughout the study period and undergo two study visits. At each study visit, participants will undergo a blood draw, blood pressure measurement and assessment of endothelial function with microiontophoresis. Participant adherence will be monitored through pill counts, text message check-ins, patient diary and biochemical monitoring.
Studietype
Registrering (Antatt)
Fase
- Fase 4
Kontakter og plasseringer
Studiekontakt
- Navn: Alisse K Hauspurg, MD
- Telefonnummer: 412-641-1381
- E-post: janickia@upmc.edu
Studer Kontakt Backup
- Navn: Sila Yavan, MS
- Telefonnummer: 4124174981
- E-post: yavans@upmc.edu
Studiesteder
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Forente stater, 15213
- Rekruttering
- University of Pittsburgh Magee-Womens Hospital
-
Ta kontakt med:
- Sila Yavan, MS
- Telefonnummer: 4124174981
- E-post: yavans@upmc.edu
-
Hovedetterforsker:
- Alisse K Hauspurg, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Postpartum individuals ≥18 years old
- Preeclampsia diagnosis
Exclusion Criteria:
- Fetal anomaly
- Multiple gestation
- Pre-pregnancy hypertension
- Allergy or contraindication to low-dose aspirin
- Pre-pregnancy diabetes
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: Placebo Group
Similar appearing placebo pill daily for 6 months will be given to subjects. |
The control group will receive similar appearing placebo daily for 6 months. |
|
Eksperimentell: Intervention Group
Low-dose [81 mg] aspirin pill daily for 6 months will be given to subjects |
The intervention group will receive low-dose [81 mg] aspirin pill daily for 6 months. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Percent of participants eligible, enrolled and retained (feasibility)
Tidsramme: Baseline to approximately 6 months postpartum
|
To determine the feasibility of conducting a single-site randomized controlled trial of 6 months of postpartum low-dose aspirin vs. placebo in women with preeclampsia. |
Baseline to approximately 6 months postpartum
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Study visit systolic BP
Tidsramme: 2 months postpartum
|
Mean study visit systolic BP |
2 months postpartum
|
|
Study visit diastolic BP
Tidsramme: 2 months postpartum
|
Mean study visit diastolic BP |
2 months postpartum
|
|
Study visit systolic BP
Tidsramme: 6 months postpartum
|
Mean study visit systolic BP |
6 months postpartum
|
|
Study visit diastolic BP
Tidsramme: 6 months postpartum
|
Mean study visit diastolic BP |
6 months postpartum
|
|
Study visit mean arterial pressure
Tidsramme: 2 months postpartum
|
Mean study visit mean arterial pressure ((2*diastolic BP + systolic BP / 3)) |
2 months postpartum
|
|
Study visit mean arterial pressure
Tidsramme: 6 months postpartum
|
Mean study visit mean arterial pressure ((2*diastolic BP + systolic BP / 3)) |
6 months postpartum
|
|
Anti-hypertensive medication use
Tidsramme: 2 months postpartum
|
Use of anti-hypertensive medication (percent of participants) |
2 months postpartum
|
|
Anti-hypertensive medication use
Tidsramme: 6 months postpartum
|
Use of anti-hypertensive medication (percent of participants) |
6 months postpartum
|
|
Therapeutic intensity score
Tidsramme: 2 months postpartum
|
Therapeutic intensity score for those on anti-hypertensive medications. Range of scores 0 to 5 (higher number indicates higher doses and number of anti-hypertensive medications; worse outcome) |
2 months postpartum
|
|
Therapeutic intensity score
Tidsramme: 6 months postpartum
|
Therapeutic intensity score for those on anti-hypertensive medications. Range of scores 0 to 5 (higher number indicates higher doses and number of anti-hypertensive medications; worse outcome) |
6 months postpartum
|
|
Mean home systolic blood pressure
Tidsramme: delivery through 6 months postpartum
|
Mean home systolic blood pressure |
delivery through 6 months postpartum
|
|
Mean home diastolic blood pressure
Tidsramme: delivery through 6 months postpartum
|
Mean home diastolic blood pressure |
delivery through 6 months postpartum
|
|
Mean home mean arterial pressure
Tidsramme: delivery through 6 months postpartum
|
Mean home mean arterial pressure |
delivery through 6 months postpartum
|
|
Mean daytime systolic blood pressure
Tidsramme: 6 months postpartum
|
Mean daytime systolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean nocturnal systolic blood pressure
Tidsramme: 6 months postpartum
|
Mean nocturnal systolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean daytime diastolic blood pressure
Tidsramme: 6 months postpartum
|
Mean daytime diastolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean nocturnal diastolic blood pressure
Tidsramme: 6 months postpartum
|
Mean nocturnal diastolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean nocturnal mean arterial pressure
Tidsramme: 6 months postpartum
|
Mean nocturnal mean arterial pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean daytime mean arterial pressure
Tidsramme: 6 months postpartum
|
Mean daytime mean arterial pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean overall mean arterial pressure
Tidsramme: 6 months postpartum
|
Mean overall mean arterial pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean overall systolic blood pressure
Tidsramme: 6 months postpartum
|
Mean overall systolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Mean overall diastolic blood pressure
Tidsramme: 6 months postpartum
|
Mean overall diastolic blood pressure on ambulatory blood pressure monitoring |
6 months postpartum
|
|
Classification of hypertension
Tidsramme: 2 months postpartum
|
Stage 1, stage 2 hypertension (percent of participants with each stage) |
2 months postpartum
|
|
Classification of hypertension
Tidsramme: 6 months postpartum
|
Stage 1, stage 2 hypertension (percent of participants with each stage) |
6 months postpartum
|
|
Endothelial function EC50%
Tidsramme: 2 months postpartum
|
EC50% from microiontophoresis |
2 months postpartum
|
|
Endothelial function EC50%
Tidsramme: 6 months postpartum
|
EC50% from microiontophoresis |
6 months postpartum
|
|
Endothelial function Emax
Tidsramme: 2 months postpartum
|
Emax from microiontophoresis |
2 months postpartum
|
|
Endothelial function Emax
Tidsramme: 6 months postpartum
|
Emax from microiontophoresis |
6 months postpartum
|
|
Endothelial function change in Emax
Tidsramme: 2 to 6 months postpartum
|
Change in Emax between visits |
2 to 6 months postpartum
|
|
Endothelial function change in EC50%
Tidsramme: 2 to 6 months postpartum
|
Change in EC50% between visits |
2 to 6 months postpartum
|
|
Change in systolic blood pressure
Tidsramme: 2 to 6 months postpartum
|
Change in study visit mean systolic blood pressure between visits |
2 to 6 months postpartum
|
|
Change in diastolic blood pressure
Tidsramme: 2 to 6 months postpartum
|
Change in study visit mean diastolic blood pressure between visits |
2 to 6 months postpartum
|
|
Change in mean arterial pressure
Tidsramme: 2 to 6 months postpartum
|
Change in study visit mean arterial pressure between visits |
2 to 6 months postpartum
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Alisse K Hauspurg, MD, UPMC Magee Women's Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Urogenitale sykdommer
- Kvinnelige urogenitale sykdommer og graviditetskomplikasjoner
- Infeksjoner
- Eklampsi
- Preeklampsi
- Hypertensjon, Graviditet-indusert
- Hypertensjon
- Kardiovaskulære sykdommer
- Vaskulære sykdommer
- Graviditetskomplikasjoner
- Toxemia
- Organiske kjemikalier
- Hydrokarboner
- Hydrokarboner, syklisk
- Hydrokarboner, aromatisk
- Fenoler
- Benzenderivater
- Salisylater
- Hydroksybenzoater
- Aspirin
Andre studie-ID-numre
- STUDY23080099
- K23HL168356 (U.S. NIH-stipend/kontrakt)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Deidentified data (including data dictionaries) will be shared at the discretion of the primary investigator. Data will include blood pressure, weight, demographics, physical activity, and pregnancy related information. Additional documents (such as the study protocol) will be made available.
IPD-delingstidsramme
Within a year after outcomes are published and no later than 3 years after the end of clinical activities.
Tilgangskriterier for IPD-deling
NHLBI data repository request process
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .